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Abstract: Background: Tumor-associated macrophages (TAMs) constitute a major portion of the
leukocyte infiltrate found in breast cancer (BC). BC cells may reprogram TAMs in a pro-angiogenic
and immunosuppressive sense. We previously showed that high expression of the ID4 protein in
triple-negative BC cells leads to the induction of a proangiogenic program in TAMs also through
the downregulation of miR-107. Here, we investigated the expression and function of the ID4
protein in TAMs. Methods: Human macrophages obtained from peripheral blood-derived monocytes
(PBDM) and mouse RAW264.7 cells were used as macrophage experimental systems. ID4-correlated
mRNAs of the TCGA and E-GEOD-18295 datasets were analyzed. Results: We observed that BC cells
determine a paracrine induction of ID4 expression and activation of the ID4 promoter in neighboring
macrophages. Interestingly, ID4 expression is higher in macrophages associated with invasive tumor
cells compared to general TAMs, and ID4-correlated mRNAs are involved in various pathways that
were previously reported as relevant for TAM functions. Selective depletion of ID4 expression in
macrophages enabled validation of the ability of ID4 to control the expression of YAP1 and of its
downstream targets CTGF and CYR61. Conclusion: Collectively, our results show that activation
of ID4 expression in TAMs is observed as a consequence of BC cell paracrine activity and could
participate in macrophage reprogramming in BC.
Keywords: Tumor-associated-macrophages; TAMs; breast cancer; BLBC; TNBC; ID4; YAP1; CTGF;
CYR61; VEGFA; ARNT
1. Introduction
Macrophages, crucial players in the adaptive immune response, are usually involved in detection
and destruction of pathogens and apoptotic cells; however, when recruited by breast cancer (BC) cells in
the tumor stroma, macrophages actively participate in tumor progression. Specifically, tumor-associated
macrophages (TAMs) are “educated”, through paracrine signaling from BC cells, to exert pro-angiogenic
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and immunosuppressive functions [1–3]. Several reports suggest that TAMs adopt a trophic
immunosuppressive phenotype that is functionally reminiscent of the alternatively activated type
II (M2) macrophages [4]. However, TAMs present great phenotypic diversity depending on the
combinations of stimuli received in the tumor microenvironment, and then multiple subpopulations of
TAMs might exist within a tumor, which probably change temporally during cancer progression and
geographically on the basis of their location within the tumor [5,6].
The helix-loop-helix ID4 protein is a member of the ID (Inhibitors of Differentiation) family of
proteins (ID-1 to ID-4) that act as dominant-negative regulators of basic helix-loop-helix transcription
factors [7]. ID4 is a negative regulator of several key pathways involved in luminal fate specification
in the mammary gland [8]. In the context of breast cancer, high ID4 expression is associated with
triple-negative breast cancer (TNBC) and basal-like breast cancer (BLBC) subtypes, where the ID4
gene might be amplified/overexpressed, and marks a subset of cancers with poor prognosis [8–10].
Functionally, it has been shown that ID4 may exert similar inhibitory effects on BRCA1 and estrogen
receptor alpha (ERα) gene expression, and, conversely, BRCA1 and ERα may demonstrate redundancy
in inhibiting ID4 gene expression in breast cancer cells and tissues [8]. Moreover, ID4 enhances the
angiogenic potential of breast cancer cells through the post-transcriptional regulation of IL8, CXCL1,
and VEGFA mRNAs and through the reprogramming of tumor-associated macrophages [11–14]. High
expression of ID4 in BC cells indeed enhances macrophage motility and leads to the activation of
a pro-angiogenic program in TAMs, which involves both the transcriptional increase of angiogenic
factors, such as granulin (GRN), and the downregulation of antiangiogenic miR-15/107 group members
(e.g., miR-107, miR-15b, and miR-195) [12]. Accordingly, ID4 mRNA levels robustly predict survival,
specifically in the subset of tumors showing high macrophage infiltration [12]. The chromosomal
region containing ID4 (6p22) is amplified in 32% of high-grade serous ovarian cancers (HG-SOC) [15],
and ID4 is over-expressed in most primary ovarian cancers and ovarian cancer cell lines, but not in
normal ovaries [16]. In HG-SOC, inhibition of ID4 in vivo suppresses the growth of established tumors
and significantly improves survival, suggesting that targeting ID4 expression is a viable therapeutic
strategy in cancers that over-express ID4 [16].
In this study, starting from the observation that breast cancer cells induce the expression of
ID4 in neighboring macrophages, we explored the mechanisms of ID4 activation and the functional
involvement of ID4 in TAM activity.
2. Materials and Methods
2.1. Cell Cultures and Transfections
Breast cancer cell lines SKBR3 (kindly provided by M. Oren’s lab, Weizmann Institute of Science,
Rehovot, Israel) MDA-MB-468 (ATCC), HCC-1954 (ATCC), and monocytic cell lines HL60, U937,
Monomac-3, and THP1 were grown at 37 ◦C with 5% CO2 and maintained in RPMI medium
(Invitrogen-GIBCO, Carlsbad, CA, USA), containing 10% heat-inactivated (HI) foetal bovine serum
(FBS) (Invitrogen-GIBCO) and penicillin/streptomycin. The OVCAR3 (ATCC) cell line was cultured as
described above in RPMI (Invitrogen-GIBCO) supplemented with 20% HI-FBS and 0.01mg/mL insulin.
The RAW264.7 cell line was cultured as described above in DMEM medium (Invitrogen-GIBCO)
10% HI-FBS (Invitrogen-GIBCO). HL60 and U937 cells were differentiated by treatment with
1,25-dihydroxyvitamin D3 (VitD3) (Sigma–Aldrich, St. Louis, MO, USA) at a concentration of
250 ng/mL for 72h. Monocytic differentiation was assessed by fluorescence-activated cell sorting (FACS)
as previously reported [12] using allophycocyanin (APC) anti-human CD11b (BD Biosciences, San
Jose, CA, USA), PerCP-Cy5.5 anti-human CD14 (BD Biosciences), and the PE-IgG1 isotype control
(eBiosciences Inc., San Diego, CA, USA) antibodies for the evaluation of CD11b–CD14 co-expression as
a marker of monocytic differentiation. A minimum of 10,000 events was collected for each sample
with a flow cytometer (CyAN ADP, Dako, Glostrup, Denmark) using Summit 4.3 software (Beckman
Coulter, Fullerton, CA, USA) for data acquisition and analysis.
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An expression vector containing the HA-tagged ID4 coding sequence [17] or control empty vector
was transfected in cancer cells using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham,
MA, USA) in ID4-overexpression experiments. RNAiMax reagent (Thermo Fisher Scientific) was used
to transfect siRNAs in BC cells. Sequences of siRNAs directed to ID4 were previously reported [12,13].
HL60 cells were treated with macrophage-activating compounds: LPS 1µg/mL (Sigma–Aldrich) or
TNF-alpha 50 ng/mL (Sigma–Aldrich) or IL4/IL13 20ng/mL (BD Biosciences).
Human peripheral blood-derived monocytes (PBDM) were isolated from blood donors using
Lymphoprep solution (Axis-Shield, Dundee, UK) followed by the isolation of CD14+ cells with the
Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Differentiation was achieved
through 1-week culturing in RPMI medium containing recombinant CSF1 (hMCSF, Cell Signaling
Technology, Danvers, MA, USA, #8929SC). Macrophages were transfected with siRNAs directed to ID4
mRNA using the TransIT-X2® Dynamic Delivery System (Mirus, Madison, WI, USA) following the
manufacturer’s instructions and were collected after 48 h.
Conditioned media (CM) from BC and OVCAR3 cells were prepared by culturing cells for 24 h
in serum-free RPMI medium. CM were centrifuged to eliminate cell residues before preparation of
aliquots and storage at −80 ◦C. When si-ID4 BC cells were used to prepare CM, we always collected
CM before 48h from transfection; the proliferation of cells was delayed after this time point under the
si-ID4 condition.
2.2. Immunohistochemistry
Collection of tumors from BC patients was reviewed and approved by the ethics committee of the
Regina Elena National Cancer Institute (IFO1270/19) and contained data for which written informed
consent was obtained from all patients. BC specimens for IHC analysis were fixed for 18–24 h in 4%
(v/v) buffered formaldehyde and were then processed with paraffin wax. ID4 and CD68 proteins were
evaluated by IHC in 5-µm-thick paraffin-embedded tissues using anti-ID4 (MAB4393, EMD Millipore,
Billerica, MA, USA) and anti-CD68 (LEICA clone 514H12) antibodies. Immunoreactions were revealed
by a streptavidin–biotin-enhanced immunoperoxidase technique (Super Sensitive MultiLink) in an
autostainer (Bond III, Leica Biosystems, Wetzlar, Germany) [18]. Diaminobenzidine (DAB) was used as
a chromogenic substrate.
2.3. Tissue Immunofluorescence
Tissue sections were deparaffinised, rehydrated, and heated in Antigen Retrieval Citra Solution,
pH 6. Then, sections were incubated for 5 min with 0.25% Triton in PBS 1%. Sections were blocked for
non-specific binding with PBS–BSA 5% for 1 h and were incubated with primary antibodies, anti-ID4
(B-5, Santa Cruz Biotechnology, Dallas, TX, USA) and anti-CD163 (D6U19, Cell Signaling), in PBS–BSA
1% for 16 h at 4 ◦C. The following day, cells were washed three times with PBS 1% followed by
incubation with Alexa Flour 488 (rabbit) and Alexa Fluor 594 (mouse)-conjugated secondary antibodies
(Molecular Probes Inc., Eugene, OR, USA) for 2 h at RT. After washing three times with PBS, sections
were counterstained with DAPI for 5 min and were mounted with Vectashield (Vector Labs, Burlingame,
CA, USA). Cells were examined under a Zeiss LSM 510 laser scanning fluorescence confocal microscope
(Zeiss, Wetzlar, Germany).
2.4. Immunocytochemistry
For immunocytochemistry assay, SKBR3 and MDA-MB-468 cells were seeded onto glass coverslips
(Marienfeld, Lauda-Königshofen, Germany) in 6-well dishes (Corning Inc., NY, USA) at 4 × 104
cells/well and were transfected with siSCR, siID4#1 or siID4#2, while differentiated HL60 cells grown
in the presence of RPMI or CM (48 h) were concentrated onto microscope slides using cytospin. Cells
were fixed with 4% formaldehyde in PBS for 15 min at RT and were then permeabilized with 0.25%
Triton X-100 in PBS for 10 min. After washing with PBS, the cells were incubated with peroxidase
inhibitor and then with anti-ID4 antibody (H70, Santa Cruz Biotechnology, Dallas, TX, USA) diluted
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1:200 in 5% bovine serum albumin (BSA)/PBS for 2 h at RT. Protein staining was revealed through a
DAB enzymatic reaction, while nuclei were counterstained with haematoxylin.
2.5. Western Blotting and Antibodies
For the Western blot analysis, cells were lysed in RIPA buffer or 8 M urea. The protein concentration
was measured using the Bio-Rad Protein Assay Kit (Hercules, CA, USA). The lysate was mixed with 4×
Laemmli buffer. Total protein extracts were resolved on polyacrylamide gel and were then transferred
onto a nitrocellulose membrane. The following primary antibodies were used: Gapdh (sc-32233),
ID4 (H70) sc-13047, ID4 (B5) sc-365656, and HA (12CA5) sc-57592 (Santa Cruz Biotechnology, Dallas,
TX, USA), ARNT (TA501147, Origene). A secondary antibody fused with horseradish peroxidase
(HRP) was used for chemiluminescence detection on a UVITEC instrument. In the VEGFA blocking
experiments, antibody (anti-VEGFA, AF-293-NA; R&D Systems, Minneapolis, MN, USA) was added
to CM and incubated for 30 min at RT before being used to culture macrophages, following the
manufacturer’s instructions.
2.6. RNA Isolation
2.6.1. RT-qPCR and PCR
RNA was isolated with Trizol (Invitrogen, Carlsbad, CA, USA), and its concentration was measured
using a NanoDrop 2000 (Nanodrop Technologies, Wilmington, DE, USA). Reverse transcription was
performed with M-MLV Reverse Transcriptase (Thermo Fisher Scientific). qPCR was carried out on an
ABI PRISM 7500 Fast Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Primers
used for PCR analyses are available upon request. The expression values of mRNAs were calculated
by the ∆∆Ct method and were normalized with housekeeping control genes (GAPDH, β-actin, H3,
Ald-A).
2.6.2. Formaldehyde Cross-Linking and Chromatin Immunoprecipitation
Formaldehyde cross-linking and chromatin immunoprecipitations were performed as previously
described [11]. Briefly, RAW264.7 or U937 cells were crosslinked using 1% formaldehyde/PBS for 10 min
at RT. Chromatin from one 150 mm dish (50% confluence) was used for each immunoprecipitated
Ab. Recovery of immune complexes was performed using Dynabeads® protein G (Invitrogen,
Carlsbad, CA, USA). The chromatin solution was immunoprecipitated with anti-ARNT (Anti-HIF1 beta
antibody-ChIP Grade ab2, abcam, Cambridge, UK), anti-H4Ac (cell signaling) or anti-H3K9me3 and
H3K9Ac (cell signaling). The mouse ID4 promoter was evaluated by real-time PCR using the following
primers: for-CCATCCTGGCCCGACTCCCA, rev-GCCACCTCGGGGAATGACGC. Enrichments were
normalized with respect to the GAPDH promoter. The human ID4 promoter was analyzed using
primers for regions A and B that were previously reported [11].
2.6.3. Bioinformatic Analysis and Statistics
The association between gene and miRNA normalized expression was assessed by calculating
the Spearman correlation coefficient. P-values were calculated using a paired, two-tailed T test,
where indicated in the figure legend, using Prism 7.00 (GraphPad Software, La Jolla California,
CA, USA).
3. Results
3.1. ID4 Expression in Breast Cancer Cells Causes ID4 Induction in TAMs
We recently reported that ID4 expression correlates with macrophage recruitment in triple-negative
breast cancer (TNBC) [12]. Within this study, we observed that TNBC tissues showing high macrophage
infiltration, evaluated using CD68 as a macrophage marker, presented ID4 protein expression not only
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in cancer cells but also in cells of the leukocyte infiltrate (Supplementary Figure S1). This prompted us
to evaluate whether the ID4 protein is expressed in macrophages infiltrating BC tissues. To this end,
we performed double immunofluorescence analysis using antibodies recognizing the ID4 protein and
the macrophage marker CD163. As shown in Figure 1A, we observed that a large part of the macrophage
population expresses the ID4 protein in the tumor stroma. We next analyzed whether the ID4 expression
level changes in macrophages cultured in conditioned medium (CM) from breast cancer cells. As shown
in Figure 1B, ID4 mRNA is induced in human peripheral blood-derived macrophages (PBDM) grown
for 48h with CM from the BC cell lines MDA-MB-468, HCC1954, and SKBR3. A similar induction is
also observed with CM from ovarian cancer cells OVCAR3 (Figure 1B). Using additional macrophage
cultures, such as those derived from U937 and HL60 cell lines, we confirmed that ID4 is induced at
mRNA and protein levels in the presence of CM from SKBR3 or MDA-MB-468 cells (Figure 1C–E and
Supplementary Figure S2A–B). Interestingly, additional well-characterized macrophage-activating
stimuli, such as LPS, TNF-alpha, and IL-4/IL-13, did not modulate ID4 expression, indicating that
this effect is not generically associated with macrophage activation but is specifically obtained as
a paracrine effect of BC cell activity (Supplementary Figure S2C). Moreover, the culture of human
fibroblasts, another cell type usually present in the tumor stroma, with CM from breast cancer cells did
not lead to ID4 induction (Supplementary Figure S2D–E), indicating that the observed effect is specific
to the monocyte/macrophage lineage.
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Figure 1. ID4 expression is induced in macrophages cultured with conditioned media from breast and
ovarian cancer cells. A. ID4 mRNA expression evaluated by RT-qPCR in macrophages, obtained from
differentiation of peripheral blood-derived monocytes (PBDM), cultured with RPMI serum free (SF), RPMI
2.5% FBS or conditioned medium (CM) from the indicated breast (MDA-MB-468, HCC-1954, SKBR3)
and ovarian (OVCAR3) cancer cells. Relative expression has been assessed normalizing over GAPDH
levels. Data are presented as mean of the expression observed in two donors ± standard error. B-C. ID4
mRNA expression in differentiated U937 cells, cultured with RPMI medium or with CM from the indicated
breast cancer cell lines for the indicated time. D. ID4 protein expression analyzed by western blot in U937
c lls cultured in RPMI medium or in CM from the i dicated breast cancer cell lines fo  24h. E. ID4 and
CD163 protein expression evaluated by immunohistochemistry on two breast cancer FFPE tissue sections.
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Figure 1. ID4 expression is induced in macrop ltured with conditioned media (CM) from
breast and ovarian cancer cells. (A) ID4 and C 163 protein expression evaluated by double
immunofluorescence in tumor stroma (FFPE tissue sections from two breast cancer cases). (B) ID4
mRNA expression evaluated by RT-qPCR in macrophages, obtained from differentiation of peripheral
blood-derived monocytes (PBDM), cultured with RPMI serum free (SF), RPMI 2.5% FBS or conditioned
medium (CM) from the indicated breast (MDA-MB-468, HCC-1954, SKBR3) and ovarian (OVCAR3)
cancer cells. Relative expression was assessed by normalizing to GAPDH levels. Data are presented as
the mean of the expression observed in two donors ± standard error. (C,D) ID4 mRNA expression in
differe tiated U937 cells, cultured with RPMI medium or with CM from the indicated breast cancer cell
lines for the indicated time. (E) ID4 protein exp ssion analyzed by Western blot in differentiated U937
cells cultured in RPMI medium or i CM from MDA-MB-468 (CM 468) or SKBR3 breast cancer cell
lines for 24 h.
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for 48h. *(P<0.05) Right panels show ID4 protein levels, evaluated by immunocytochemistry, in control (si-
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SCR) or ID4-depleted (si-ID4) MDA-MB-468 cells. **(P<0.005). Right panels show ID4 protein levels,
evaluated by immunocytochemistry, in control (si-SCR) and ID4-depleted (si-ID4#1) MDA-MB-468 cells
used for the preparation of CM. C. ID4 mRNA expression on PBDM cultured with CM from control (EV)
and ID4-HA-overexpressing MDA-MB-468 cells for the indicated days. D-E. ID4 mRNA (D) and protein
(E) expression evaluated on macrophages obtained from HL60 differentiation and cultured in CM from
control (EV) or ID4-HA-overexpressing (ID4-HA) MDA-MB-468 cells. F-G. ID4 expression in
differentiated HL60 cells cultured in CM from control (si SCR) or ID4-depleted (si-ID4 #1, si-ID4 #2)
SKBR3 cells, evaluated by RT-qPCR (F) and immunocytochemistry (G). **(P<0.005)***(P<0.0005). P-
values were calculated by two-tailed t-test on 3 biological replicates.
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Figure 2. Dependency between ID4 expression levels in BC cells and TAMs. (A) ID4 mRNA expression
in macrophages derived from PBDM co-cultured with control (si-SCR) or ID4-depleted (si-ID4) SKBR3
cells for 48 h. Right panels show ID4 protein levels, evaluated by immunocytochemistry, in control
(si-SCR) and ID4-depleted (si-ID4#1) SKBR3 cells used for the co-culture. (B) ID4 mRNA expression in
differentiated HL60 cells and in monomac-6 cells cultured with RPMI medium or with CM from the
control (si-SCR) or ID4-depleted (si-ID4) MDA-MB-468 cells. Right panels show ID4 protein levels,
evaluated by immunocytochemistry, in the control (si-SCR) and ID4-depleted (si-ID4#1) MDA-MB-468
cells used for the preparation of CM. (C,D) ID4 mRNA (C) and protein (D) expression evaluated by
RT-qPCR and immunocytochemistry, respectively, in differentiated HL60 cells cultured with RPMI
medium or with CM from control (si-SCR) or ID4-depleted (si-ID4#1 and si-ID4#2) SKBR3 cells.
(E) ID4 mRNA expression on PBDM cultured with CM from control (EV) and ID4-HA-overexpressing
MDA-MB-468 cells for the indicated number of days. F-G. ID4 mRNA (F) and protein (G) expression
evaluated on macrophages obtained from HL60 differentiation and cultured in CM from control (EV)
or ID4-HA-overexpressing (ID4-HA) MDA-MB-468 cells. * (p < 0.05), ** (p < 0.005). P-values were
calculated by a paired two-tailed t-test.
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Interestingly, co-culture of macrophages with breast cancer cells whose ID4 expression has been
inhibited by siRNA transfection (si-ID4#1, si-ID4#2) led to a significantly attenuated ID4 induction
in macrophages, compared to co-culture with control cells (si-SCR) (Figure 2A–D). On the contrary,
PBDM cultured with conditioned medium (CM) derived from ID4-overexpressing breast cancer cells
(ID4-HA) showed a much stronger and time-dependent ID4 mRNA induction compared to the control
CM (empty vector, EV) (Figure 2E). ID4 overexpression effects were recapitulated in various additional
macrophage experimental systems (Figure 2F–G and Supplementary Figure S2F–G). Together, these
results demonstrate that breast cancer cells determine a paracrine induction of ID4 expression in
macrophages. This induction is strictly dependent on the ID4 expression levels in breast cancer cells.
3.2. ID4 Induction in Macrophages Depends on ID4 Promoter Activation
As we observed that ID4 expression in macrophages is strongly related to ID4 levels in BC cells,
we wondered whether ID4 induction in macrophages depended on activation of the macrophage
endogenous ID4 promoter or on the transfer of the ID4 mRNA/protein from cancer cells to macrophages.
To address this, we first over-expressed HA-tagged ID4 protein in cancer cells, collected the CM and
evaluated whether the ID4-HA protein was transferred to macrophages cultured with this CM. To this
end, we used an antibody recognizing the HA-tag, present only on the protein exogenously expressed
in cancer cells. As shown in Figure 3A–B, we did not detect the ID4-HA protein in macrophages,
despite that ID4 mRNA was efficiently induced, indicating that the ID4 protein was not transferred
from cancer cells to macrophages. Next, we cultured the mouse macrophage cell line RAW264.7 with
CM from human BC cells and we evaluated whether the human or murine ID4 mRNA was detectable
in mouse macrophages. As shown in Figure 3C, primers recognizing mouse ID4 mRNA were able to
detect ID4 induction in macrophages, while human-specific primers did not detect any ID4 mRNA in
RAW264.7 cells. Together, these results indicate that no ID4 protein or mRNA transfer occurred from
cancer cells to macrophages.
We then investigated the mechanism leading to ID4 expression activation in macrophages.
Previous studies from our group showed that the transcriptional regulator ARNT (also known as
HIF1-beta) is controlled by ID4-dependent microRNAs in macrophages [12]. Interestingly, we also
observed that ARNT behaves similarly to ID4 mRNA in macrophages cultured in the presence of
CM from control (si-SCR) or ID4-depleted (si-ID4) BC cells (Figure 3D). Moreover, as we previously
observed that the ID4 protein controls VEGFA expression in breast cancer cells [13], and VEGFA in
turn participates in the reprogramming of macrophages in a pro-angiogenic sense [12], we decided
to investigate the impact of VEGFA on ID4 and ARNT expression in macrophages. As shown in
Figure 3E, addition of the VEGFA blocking antibody to the CM used to culture macrophages impaired
the induction of both ID4 and ARNT compared to control IgG. On the basis of these results, we explored
whether ARNT could participate in ID4 transcriptional regulation in macrophages. To address this
question, we analyzed the ID4 promoter sequence and observed the existence of various AhR/ARNT
binding sites. We then evaluated whether ARNT was recruited on the ID4 promoter in macrophages
cultured in CM from MDA-MB-468 BC cells. ChIP experiments highlighted that the ARNT protein was
indeed recruited on the two analyzed regions of the ID4 promoter, enclosing AhR/ARNT consensus
sequences, specifically in macrophages cultured with CM (Figure 3F–G). ChIP analysis of acetylated
histones showed an increased acetylation degree only in region B of the ID4 promoter (Figure 3H–I).
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Figure 3. (A,B) ID4 expression analyzed by Western blot (A) and RT-qPCR (B) in recipient H1299
cells, transfected with an empty vector (EV) or an HA-tagged ID4 expression vector, and in U937
cells cultured with RPMI, CM from H1299-EV or CM from H1299-ID4-HA cells. (C) ID4 mRNA
expression in RAW264.7 mouse macrophages grown with RPMI medium or with CM from human
breast cancer cells evaluated with primers recognizing the ouse (Mm assay) or hu an (Hs assay)
ID4 cDNA sequence. (D) ID4 and ARNT mRNA expression evaluated by RT-qPCR in differentiated
U937-derived m crophages cultured with RPMI or with conditioned medium (CM) from control
(si-SCR) or ID4-depleted (si-ID4) MDA-MB-468 breast cancer cells for 48 h. Data were normalized
with respect to GAPDH expression. p-values were calculated on the fold decrease between si-SCR
and si-ID4 conditions. (E) ID4 and ARNT mRNA expression evaluated by RT-qPCR in differentiated
U937-derived macrophages cultured with RPMI or with conditioned medium (CM) from MDA-MB-468
breast cancer cells in the presence of the control antibody (IgG) or VEGFA blocking antibody (VEGFA
Ab) for 48h. Data were normalized with respect to GAPDH expression. p-values were calculated on
the fold decrease between IgG and VEGF Ab conditions. (F) ARNT protein expression evaluated by
Western blot in differentiated U937 cells cultured with R MI or with CM from MDA-MB-468 (CM 468)
or SKBR3 (CM SK) for 24h. (G–I) Chromatin immunoprecipitation analysis of differentiated U937 cells
cultured with RPMI or with conditioned medium (CM) from MDA-MB-468 breast cancer cells for 24h.
IP was performed with anti-ARNT (G) or anti-acetylated histone H4 or anti-acetylated histone H3K9
(H,I). Two regions of the ID4 promoter located nearly at −500 (region A) and −250 (region B) bp from
TSS were analysed. ** (p < 0.005). P-values were calculated by a paired two-tailed t-test.
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3.3. Identification of ID4-Associated Pathways in TAMs
To investigate the functional relevance of ID4 expression in TAMs, we next evaluated publicly
available datasets. A study by Ojalvo S and colleagues [19] included gene expression analysis of
macrophages associated with invasive tumor cells compared to general TAMs from PyMT mammary
tumors (E-GEOD-18295). In this dataset, we interestingly observed that the ID4 mRNA level was
significantly higher in invasive vs. general TAMs (Figure 4A). A similar behavior was observed
for CXCL1, previously identified, together with IL8, as targeted by ID4 in BC cells [11] (Figure 4A).
To identify genes correlated with ID4 in macrophages and relevant to human BC, we extracted all the
ID4-correlated mRNAs in the E-GEOD-18295 dataset and, subsequently, we intersected this list with
that of ID4-correlated genes in basal-like BC (BLBC) from the TCGA study. BLBC was chosen, as ID4 is
specifically upregulated and associated with decreased metastasis-free survival in this subtype [8–10].
We identified 268 and 84 mRNAs that were positively and negatively correlated with ID4, respectively,
in both datasets. Interestingly, we noticed that many components of the extracellular matrix (ECM)
were positively correlated with ID4 (such as collagens COL2A1, COL4A1, COL4A2, COL5A2, COL8A1,
COL9A2, COL9A3 and laminins LAMA4, LAMB1), suggesting that ID4 might contribute to ECM
stiffening in BLBC. To identify enriched pathways among genes positively correlated with ID4, we
interrogated ConsensusPathDB software, thus highlighting that ID4 associates with various pathways
related to the interaction between membrane receptors and the extracellular matrix (ECM-receptor
interaction) as well as with cell motility (focal adhesion, Amoebiasis) (Table 1).
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Table 1. Pathways enriched among the genes positively correlated to ID4 in both the E-GEOD-18295
dataset and in basal-like breast cancers of the TCGA cohort. Analysis was performed using
ConsensusPathDB, interrogating the KEGG pathway database (cutoff, n = 8 genes).
p-Value Pathway ID4-Correlated Genes
3.44 ×10−08 ECM-receptor interaction
THBS2; LAMA4; ITGA1; COL9A2; COL9A3; AGRN;
ITGA10; COL4A2; COL4A1; LAMB1; COL2A1
1.39 × 10−06 PI3K-Akt signaling pathway
COL4A1; ERBB3; PDGFD; PIK3R1; GHR; COL9A2;
LAMB1; THBS2; COL9A3; CHRM1; GNG7; ITGA10;
COL4A2; MAGI1; ITGA1; FGF7; LAMA4;
COL2A1; LPAR4
1.47 × 10−06 Amoebiasis
PLCB1; TGFB2; PLCB4; PIK3R1; ACTN4; COL4A2;
COL4A1; GNA11; LAMB1; LAMA4
1.68 × 10−06 Focal adhesion
THBS2; LAMA4; PIK3R1; ACTN4; ITGA1; COL9A2;
COL9A3; ITGA10; COL4A2; COL4A1; LAMB1;
PDGFD; COL2A1; MYL9
4.92 × 10−05 Human papillomavirus infection
DLG1; COL4A1; THBS2; LAMA4; MAGI1; FZD6;
ITGA1; COL9A2; COL9A3; ITGA10; COL4A2; PIK3R1;
FZD9; LAMB1; COL2A1; HEY1
5.82 × 10−05 Protein digestion and absorption
ELN; COL9A2; COL9A3; ATP1B1; COL5A2; COL4A2;
COL4A1; COL2A1
8.20 × 10−05 Vascular smooth muscle contraction
PLCB1; NPR2; PLCB4; ARHGEF12; GNA11; EDNRA;
PPP1R14A; CALD1; MYL9
8.48 × 10−05 Regulation of actin cytoskeleton
ARHGEF12; PDGFD; ACTN4; LIMK2; ITGA1;
CHRM3; CHRM1; ITGA10; PIK3R1; FGF7;
LPAR4; MYL9
3.3 × 10−04 Pathways in cancer
PLCB1; ARHGEF12; BMP4; PLCB4; COL4A1; FZD6;
FZD9; LAMB1; TGFB2; GNG7; JUP; COL4A2; PIK3R1;
GNA11; FGF7; LAMA4; EDNRA; LPAR4; HEY1
4.8 × 10−04 Hippo signaling pathway
DLG1; TGFB2; BMP4; FZD6; FZD9; CTGF; SNAI2;
FRMD6; YAP1
3.09 × 10−03 cGMP-PKG signaling pathway
PLCB1; NPR2; PLCB4; SRF; ATP1B1; GNA11;
EDNRA; MYL9
3.4. ID4 Controls the Expression of Hippo Pathway Members YAP1, CTGF, and CYR61 in TAMs
Of note, our bioinformatic analysis revealed that YAP1, a member of the Hippo pathway, and its
downstream bona fide transcriptional targets, encoding the matricellular proteins CTGF and CYR61,
are positively correlated with ID4 in macrophages. This particularly caught our attention given that
the YAP1-dependent cascade is an important player in tissue stiffness. Correlation between ID4 and
YAP1, ID4 and CTGF, ID4 and CYR61 in the E-GEOD-18295 and TCGA-basal datasets is shown in
Figure 5A–B. Association between ID4 and Hippo pathway members might rely on the fact that
they are commonly regulated by an upstream regulatory factor or that they are interdependent. To
address this, we explored whether ID4 controls the expression of ECM remodeling factors YAP1, CTGF,
and CYR61 in macrophages by depleting ID4 expression in PBDM-derived macrophages. As shown in
Figure 5C, expression of YAP1, CTGF, and CYR61 mRNAs decreased in macrophages depleted of ID4
expression by siRNA transfection, indicating that ID4 controls the expression of these genes, while no
modulation of macrophage receptor CCR2 was observed.
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B2 (EphB2), and neuropilin-2 (NRP2) [12]. We also investigated the mechanisms leading to ID4 
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Figure 5. (A) Graph showing the correlation (Spearman coefficients) between ID4 and CTGF (upper
graph), YAP1 (middle graph) or CYR61 (lower graph) in the geod18295 dataset. Black and red dots
refer, respectively, to general and invasive TAMs. (B) Graph showing the correlation (Spearman
coefficients) between ID4 and CTGF (upper graph), YAP1 (middle graph) or CYR61 (lower graph) in the
TCGA dataset, considering the subgroup of basal-like breast tumors with high macrophage infiltration
(CD68-high). (C) Expression of ID4, YAP1, CTGF, CYR61, and CCR2 in macrophages depleted of ID4
expression by siRNA delivery and in control macrophages (si-SCR). Data obtained from the analysis of
macrophages from ≥ 4 donors are presented. * (p < 0.05), ** (p < 0.005). p-values were calculated by a
paired two-tailed t-test.
4. Discussion
In this study, we show that expression of the ID4 protein is induced in macrophages cultured with
conditioned growth medium from b a t and ovarian canc r cells. Interestingly, efficient induction
of ID4 i macrophages is obtained only if high levels f ID4 are present in breast cancer cells. This
observation fits well into the context of our previous study that highlighted how high ID4 expression
in BC cells causes induction of proangioge ic factors in neighboring macrophages [12]. ID4 induction
could then be in luded in the reprogramming of macrophages caused by ID4 expression in BC
cells, also nvolving the activation of other factors such as granulin (GRN), ephrin B2 (EphB2),
and neuropilin-2 (NRP2) [12]. We also investigated the mechanisms le ding to ID4 induction i
macrophages. Specifically, we observed that th VEGFA present in conditioned edium is required
for ID4 i duction in macrophages. We previously reported that VEGFA xpression s mo ulated by
ID4 in cancer cells [13]. VEGFA then acts s the mediator that confers to ID4 protein in cancer cells
the ability to cause ID4 induction in macrophages. Howev r, we observed that depletion of ID4 i
cancer cells only partially impairs the induction of ID4 in macrophages. This could rely on the fact that
VEGFA expression in cancer cells is strictly regulated and depends not only on ID4 but also on several
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other regulatory pathways, and it is possible that ID4 depletion is not sufficient to completely abolish
VEGFA activity and, consequently, ID4 expression in macrophages.
Of note, we observed that VEGFA also controls the expression of ARNT in macrophages. ARNT
(aryl hydrocarbon receptor nuclear translocator), also known as HIF1B, is a transcription factor that
interacts with the ligand-bound AhR (aryl hydrocarbon receptor) protein and facilitates its translocation
to the nucleus, where it modulates the expression of genes involved in xenobiotic metabolism. Recently,
AhR has been shown to support BC growth by controlling reactive oxygen species (ROS) levels and the
tumor-promoting features of macrophages [20]. ARNT is also a co-factor for transcriptional regulation
by hypoxia-inducible factor 1 (HIF1A). Specifically, we found that ARNT expression in macrophages
is, similar to ID4, decreased by VEGFA blocking in conditioned medium. As ARNT is a target of
microRNA-107 (miR-107) [12,21], its downregulation in the presence of VEGFA blocking probably
relies on upregulation of miR-107, which occurs in this experimental condition, as we previously
reported [12]. Interestingly, we observed that the ARNT protein, which increases in macrophages
in the presence of CM from BC cells, is also recruited onto ID4 promoter, containing AhR/ARNT
response elements, suggesting its involvement in the transcriptional induction of ID4 occurring as a
consequence of paracrine signaling from BC cells. It will be of interest to further determine whether
ARNT cooperates with AhR in the control of the ID4 promoter.
To evaluate the possible functional implication of the ID4 protein in macrophages, we searched
for genes and pathways correlated with ID4 in a tumor-associated macrophage dataset as well as in the
TCGA dataset, the latter being necessary to identify ID4-associated factors relevant for human cancer.
This was performed specifically on the basal-like subgroup of BC, as our group and others previously
showed that ID4 is a powerful prognostic indicator in this subgroup [9,10,12,13]. Bioinformatic analysis
enabled us to highlight some genes of the Hippo pathway that are positively associated with ID4 in
these datasets. These genes are particularly interesting to us, as they have been extensively shown
to play crucial roles in cancer cells, including TNBC cells, and also in immune cells of the tumor
microenvironment [22–24]. The co-activator YAP recently emerged as a mechanosensor and a key
mediator of the biological effects that are observed in response to ECM elasticity and cell shape [25,26].
Moreover, high tumor stiffness and F-actin polymerization correlate with increased activity of YAP [27].
Interestingly, tissue stiffness is caused by collagen deposition and by the activity of lysyl oxidases [28],
which increase collagen crosslinking. Importantly, tumor fibrosis has been shown to be controlled
by macrophages in cancer and to play a crucial role in immune escape [29–31]. In the present study,
we interestingly highlighted on the one hand that ID4 expression in macrophages is associated with
high levels of proteins of the ECM, such as collagens and laminins, as well as of the focal adhesions,
and on the other hand that the ID4 protein increases the mRNA level of YAP1 and its downstream
targets CTGF and CYR61 in macrophages. As CTGF and CYR61 are matricellular proteins important
for ECM-cell interaction [32], we aim to investigate in our future studies if the ID4-driven axis in
macrophages contributes to the remodeling of the ECM in breast tumors and to decipher the specific
roles of the ID4 protein in the ECM-Hippo signaling cascade in TAMs.
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